{"nctId":"NCT02636595","briefTitle":"The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4)","startDateStruct":{"date":"2015-11","type":"ACTUAL"},"conditions":["Hepatitis C Virus"],"count":121,"armGroups":[{"label":"ABT-493/ABT-530","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-493/ABT-530"]}],"interventions":[{"name":"ABT-493/ABT-530","otherNames":["ABT-493 also known as glecaprevir","ABT-530 also known as pibrentasvir","MAVYRET"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Screening laboratory result indicating hepatitis C virus (HCV) genotype (GT) 4, 5, or 6 infection.\n2. Chronic HCV infection.\n3. HCV treatment-naïve or treatment experienced (interferon \\[IFN\\] or pegylated interferon \\[pegIFN\\] with or without ribavirin \\[RBV\\]; sofosbuvir \\[SOF\\] plus RBV with or without pegIFN).\n4. Non-cirrhotic participants.\n\nExclusion Criteria:\n\n1. History of severe, life-threatening or other significant sensitivity to any excipient of the study drugs.\n2. Female who is pregnant, planning to become pregnant during the study, or breastfeeding; or male whose partner is pregnant or planning to become pregnant during the study.\n3. Recent (within 6 months prior to study drug administration) history of drug or alcohol abuse that could preclude adherence to the protocol in the opinion of the investigator.\n4. Positive test result at Screening for hepatitis B surface antigen (HBsAg) or anti-human immunodeficiency virus antibody (HIV Ab).\n5. Co-infection with more than one HCV genotype.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)","description":"SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \\[\\<LLOQ\\]) 12 weeks after the last dose of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With On-treatment Virologic Failure","description":"On-treatment virologic failure was defined as confirmed increase of \\> 1 log(subscript)10(subscript) IU/mL above the lowest value post-baseline HCV RNA during treatment; confirmed HCV RNA ≥ 100 IU/mL after HCV RNA \\< LLOQ during treatment, or HCV RNA ≥ LLOQ at end of treatment with at least 6 weeks of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Post-treatment Relapse","description":"Post-treatment relapse was defined as confirmed HCV RNA ≥ LLOQ between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA levels \\< LLOQ at the end of treatment, excluding reinfection.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":121},"commonTop":["HEADACHE","FATIGUE","NAUSEA","ASTHENIA","PRURITUS"]}}}